Alnylam Pharmaceuticals, Inc.
ALNY
Rang in aandelen
#787
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily... Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.
Aandeelprijs
$230.76
Laatst gesynchroniseerd: 2026-10-20
Marktkapitalisatie
$30.88B
Verandering (1 dag)
-1.08%
Verandering (1 jaar)
-51.32%
Land
US
Handel Alnylam Pharmaceuticals, Inc. (ALNY)
Categorie
Healthcare
Aantal uitstaande aandelen voor Alnylam Pharmaceuticals, Inc. (ALNY)
Aantal uitstaande aandelen per June 2026: 133.24M
Volgens de laatste financiële rapporten en de aandelenkoers van Alnylam Pharmaceuticals, Inc. bedraagt het huidige aantal uitstaande aandelen 133.24M. Aan het einde van December 2024 had het bedrijf 127.65M uitstaande aandelen. Het aantal uitstaande aandelen wordt meestal beïnvloed door aandelensplitsingen en terugkoop van aandelen.
Geschiedenis van uitstaande aandelen van Alnylam Pharmaceuticals, Inc. (ALNY) van 2002 tot 2026
Uitstaande aandelen aan het einde van elk jaar
| Jaar | Uitstaande aandelen | Wijzigen |
|---|---|---|
| 2026 (TTM) | 133.24M | 1.71% |
| 2025 | 131.00M | 2.63% |
| 2024 | 127.65M | 2.20% |
| 2023 | 124.91M | 2.64% |
| 2022 | 121.69M | 2.73% |
| 2021 | 118.45M | 3.01% |
| 2020 | 114.99M | 5.24% |
| 2019 | 109.26M | 8.62% |
| 2018 | 100.59M | 11.08% |
| 2017 | 90.55M | 5.79% |
| 2016 | 85.60M | 1.91% |
| 2015 | 83.99M | 13.08% |
| 2014 | 74.28M | 20.68% |
| 2013 | 61.55M | 22.40% |
| 2012 | 50.29M | 18.57% |
| 2011 | 42.41M | 0.88% |
| 2010 | 42.04M | 0.98% |
| 2009 | 41.63M | 1.35% |
| 2008 | 41.08M | 6.26% |
| 2007 | 38.66M | 21.22% |
| 2006 | 31.89M | 45.29% |
| 2005 | 21.95M | 84.66% |
| 2004 | 11.89M | 1,160.89% |
| 2003 | 942.67K | 184.50% |
| 2002 | 331.34K | 0.00% |
Uitstaande aandelen van vergelijkbare bedrijven of concurrenten
| Bedrijf | Uitstaande aandelen | Verschil | Land |
|---|---|---|---|
| 253.90M | 90.55% |
US
|
|
| 396.00M | 197.20% |
US
|
|
| 478.91M | 259.42% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -53.33% |
NL
|
